• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2023

View Archived Issues
PET imaging of RELN-COLBOS (H3447R) carrier brain showing limited aggregation of tau

Reelin’ in druggable protective pathways with second Alzheimer’s ‘escapee’

Investigators have identified a second individual who remained cognitively normal into his late 60s despite having the PSEN1 E280A mutation, which causes a familial version of early-onset Alzheimer’s disease (AD). The likely source of protection, a mutation in a gene called Reelin, is distinct from the protective mechanism identified in the first case of an individual who was protected from the effects of PSEN1 E280A. That case was reported in 2019. Read More

Acesion Pharma reports preclinical data with second-generation SK channel inhibitor AP-31969 for atrial fibrillation

Acesion Pharma ApS has announced promising data from preclinical studies with AP-31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence. Acesion aims to develop a novel drug for AF that solves the risk of proarrhythmia associated with existing drugs. Read More
Skin, tissue layer illustration

TRPV3 inhibitor KM-001 shows activity in keratoderma and itch models

TRPV3 is a temperature-sensitive transient receptor potential (TRP) ion channel that functions as a regulator of skin homeostasis. The epidermal overexpression of TRPV3 is linked to dermatological conditions with increased inflammation signals such as dermatitis, hyperkeratosis, keratoderma or pruritus. Read More
CAR T cell

New Fas-TNFR chimeras overcome Fas ligand-mediated apoptosis and increase CAR T-cell efficacy

A new study has discovered a promising approach to improve the efficacy of adoptive cell therapies for cancer. The research, published in Molecular Therapy: Nucleic Acids, describes the development of novel Fas-TNFR chimeras acting as decoys for the Fas ligand and preventing it from binding to its natural receptor on the surface of chimeric antigen receptor (CAR) T cells. Read More

Voronoi patents new RIPK1 inhibitors

Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others. Read More

BioWorld Science reader feedback needed

Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld Science an even more useful and valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take less than 5 minutes. You can click through to the question here. Read More
Colorized scanning electron microscope image of regulatory T cells and antigen-presenting cells.

Dualyx completes series A financing to advance Treg therapies for autoimmune diseases

Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates. Read More

Preclinical data published on BYON-4228, a first-in-class pan-allelic SIRPα antibody with no SIRPγ reactivity

Researchers from Byondis BV and Sanquin Bloedvoorziening have published preclinical data on a new signal-regulatory protein α (SIRPα)-directed antibody, BYON-4228. Read More

Lhotse Bio describes new LPAR1 antagonists

Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others. Read More
3D illustration of kidney cross section

Rona and Keymed Biosciences collaborate on siRNA therapeutics for glomerulonephritis

Rona Therapeutics Inc. and Keymed Biosciences Co. Ltd. have established a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis. The collaboration will leverage both companies’ scientific and technological expertise and will build on Rona’s proprietary platform in RNAi targeting liver and extrahepatic tissues. Read More

Chiesi Farmaceutici divulges new DDR inhibitors for fibrosis

Chiesi Farmaceutici SpA has synthesized pyrrolidine derivatives acting as discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis and idiopathic pulmonary fibrosis (IPF). Read More

Azura Ophthalmics presents new codrugs for eye and dermatological disorders

Azura Ophthalmics Ltd. has divulged codrugs consisting of an immunomodulator moiety and a keratolytic agent reported to be useful for the treatment of eye and dermatological disorders. Read More
Colorized scanning electron microscope image of an osteosarcoma cell.

Novel ALPL1-targeting CAR therapies show promise in metastatic osteosarcoma

Osteosarcoma (OS) is an aggressive cancer type, with frequent metastasis seen in the lungs, and for which two-thirds of metastatic patients fail to achieve durable responses and die due to the disease. Read More

Researchers in Spain discover new antimalarials

Researchers from Fundacio Privada Instituto de Salud Global Barcelona (ISGLOBAL), Institut de Bioenginyeria de Catalunya (IBEC) and Universitat de Barcelona have described compounds reported to be useful for the treatment of malaria. Read More

Preclinical characterization of BAY-2965501, a potent and selective DGK-ζ inhibitor

Bayer AG’s diacylglycerol kinase ζ (DGK-ζ) inhibitor BAY-2965501 is being developed as a first-in-class cancer immunotherapy candidate. The company recently presented preclinical data on the compound, which supported advancement of the candidate into clinical testing, with a first-in-human phase I study in solid tumors underway (NCT05614102). Read More
HIV infected cell

Self-assembling nanoparticles presenting glycan-trimmed envelope trimers as HIV-1 vaccine candidates

The HIV-1 envelope glycoprotein (Env) mediates cell entry and is the target of the host humoral immune response. Functional Env is a trimer of noncovalent gp120-gp41 heterodimers. Rational trimer design has transformed the HIV-1 vaccine research field and has helped understand Env structure and immunogenicity. Uncleaved prefusion-optimized (UFO) trimers have been shown to stabilize diverse HIV-1 Env glycoproteins. Read More

Other news to note for May 15, 2023

Additional early-stage research and drug discovery news in brief, from: Cellectis, Protagonist Therapeutics. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe